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In Human Erythroid Massive Ampliﬁcation (HEMA) cultures, AB mononuclear cells (MNC) generate 1-log more erythroid cells
(EBs) than the corresponding CD34
pos cells, suggesting that MNC may also contain CD34
neg HPC. To clarify the phenotype
of AB HPC which generate EBs in these cultures, ﬂow cytometric proﬁling for CD34/CD36 expression, followed by isolation
and functional characterization (colony-forming-ability in semisolid-media and fold-increase in HEMA) were performed.
Four populations with erythroid diﬀerentiation potential were identiﬁed: CD34posCD36neg (0.1%); CD34posCD36pos (barely
detectable-0.1%); CD34
negCD36
low (2%) and CD34
negCD36
neg (75%). In semisolid-media, CD34
posCD36
neg cells generated
BFU-E and CFU-GM (in a 1:1 ratio), CD34
negCD36
neg cells mostly BFU-E (87%) and CD34
posCD36
pos and CD34
negCD36
low
cells were not tested due to low numbers. Under HEMA conditions, CD34posCD36neg,C D 3 4 posCD36pos,C D 3 4 negCD36low and
CD34negCD36neg cells generated EBs with fold-increases of ≈9,000, 100, 60 and 1, respectively, and maturation times (day with
>10% CD36highCD235ahigh cells) of 10–7 days. Pyrenocytes were generated only by CD34neg/CD36neg cells by day 15. These results
conﬁrm that the majority of HPC in AB express CD34 but identify additional CD34neg populations with erythroid diﬀerentiation
potential which, based on diﬀerences in fold-increase and maturation times, may represent a hierarchy of HPC present in AB.
1.Introduction
Hematopoiesis is deﬁned as the orderly sequence of events
that replenishes the cellular elements of the blood on a daily
basis [1]. Under steady-state conditions, the bone marrow
provides the microenvironmental cues that allow hemato-
poieticstemcellstogenerateahierarchy ofcells(thehemato-
poietic progenitor cells, HPCs) progressively more restricted
in their proliferation and lineage maturation potential [2].
In addition, bone marrow contains very rare precursor cells
with the potential to generate hematopoietic stem cells [3].
Human stem cell precursors and stem cells are functionally
deﬁned by surrogate assays in animal models [4], while
HPCs with diﬀerent proliferation/maturation potential are
deﬁned by semisolid cultures that model the hematopoietic
processinvitro [5]. These functional in vitro assays provided
the basis for the identiﬁcation and prospective isolation of
ah i e r a r c h yo fd i ﬀerent hematogenic populations present in
bone marrow [6]. Based on number and lineage of the cells
generated and of the time required for their generation,
semisolid assays identify a series of HPCs: HPCs able to
generate large colonies (>30,000 cells) comprising cells of
multiple lineages (the colony-forming unit, granulocytic-
erythroid-megakaryocitic-monocytic, CFU-GEMM) by day
15–18,thosewhich generateerythroid bursts(approximately
5,000 cells, burst-forming unit erythroid BFU-E) and granu-
lomonocytic colonies (colony forming unit, granulomono-
cytic, CFU-GM) by day 12–15, and ﬁnally those which
generate clusters (50–200 cells) composed only by eryth-
roid (colony-forming unit, erythroid, CFU-E), granulocytic
(CFU-G) or monocytic (CFU-M) cells by day 8 [5].
CD34 is an antigen expressed by HPCs of all types whose
expression is lost at the CFU-E level [5, 6]. CFU-GEMM
express also CD38 but do not express the α subunit of2 Stem Cells International
the interleukin-3 (IL-3) receptor, which is acquired during
the transition of these cells to BFU-E, CFU-GM, and
CD45RA [7, 8], which is speciﬁcally expressed by BFU-E
[5, 6].CD36is anantibody thatrecognizes thrombospondin,
the receptor for the malarial parasite whose expression is
activated within a few hours of exposure to erythropoietin
(EPO) [9]. Although it is conceivable that CD36 is expressed
byerythroidcellsofalltypes,howitsexpressionismodulated
during the transition from CFU-GEMM to CFU-E is not
known. HPCsmayegress from thebonemarrow into thecir-
culation [2]. However, since maturation alters the adhesion
receptor proﬁle of the cells and their aﬃnity for the marrow
niches, HPCs are released from the marrow with diﬀerent
eﬃcienciesand their frequency in blood may not correspond
to that of the marrow [10]. The majority of erythroid HPCs
in the marrow are CFU-E, but the majority (>90%) of those
in blood are BFU-E [11].
The HPCspresentin adultperipheral blood(AB)are dis-
cardedduringtheleukoreductionprocessusedtopreparered
blood cells for transfusion. Discarded AB HPCs are used in
several liquid culture systems to generate great numbers of
lineage-restricted precursorstostudyhematopoiesis[12,13].
More recently, it has been realized that AB HPCs discarded
in the buﬀy coat from a single donation cultured in the
presence of dexamethasone (DXM) and estradiol (ES), and
in addition to stem cell factor (SCF), IL-3 and EPO (human
erythroid massive ampliﬁcation, HEMA, culture) [14]m a y
generate erythroblasts (EBs) in numbers suﬃcient for 3–50
transfusions [15], paving the way for an important area of
translational medicine: production of alternative transfusion
products ex vivo. Although both AB mononuclear (MNC)
and CD34pos cells generate great numbers of EBs in HEMA
culture, the total number of erythroid cells generated by
CD34pos cells is on average 1-log lower than that generated
by MNC [13]. This observation has been ascribed to loss of
HPCs with erythroid diﬀerentiation potential (erythroid
precursor cells, EPC) during the CD34 selection procedure
and/or to the existence of circulating CD34neg EPC. The
second hypothesis is supported by a recent report indicating
that AB CD34neg cells may diﬀerentiate into EBs under
HEMA conditions generating more EBs than the corre-
sponding CD34pos cells [16] .T h ep h e n o t y p eo ft h eC D 3 4 neg
cells with erythroid potential present in AB buﬀyc o a tsi sn o t
known.
The aimofourstudy wastofurtherclarify thephenotype
of the HPCs/EPC present in AB MNC and to evaluate their
contribution to the generation of EBs under HEMA condi-
tions. Flow cytometric proﬁling for CD34 and CD36 expres-
sion of AB MNC followed by functional characterization
(colony-forming ability in semisolid media and fold increase
in HEMA) of the prospectively isolated populations was
perfomed. The results presented indicate that CD34/CD36
proﬁling identiﬁes a hierarchy of EPC in AB.
2.Materialsand Methods
2.1. Human Subjects. Peripheral blood was collected from
10 normal adult donors at the transfusion center of
“La Sapienza” University (Rome, Italy) according to guide-
lines established by institutional ethical committees.
2.2. Cell Separation. Mononuclear cells (MNCs) were sep-
arated by centrifugation over Ficoll-Hypaque (Amersham
Pharmacia Biotec, Uppsala, Sweden). MNC were ﬁrst anti-
genically proﬁled for CD34/CD36 expression by standard
ﬂow cytometric techniques and MNC populations with
diﬀerent CD34/CD36 proﬁles subsequently separated by a
combination of magnetic bead separation and sorting as de-
scribed in Figure 1. For ﬂow cytometrical proﬁling, MNC
were suspended in Ca2+/Mg2+-free phosphate-buﬀered sa-
line,supplementedwith1%BSA,2mmol/Lethylenediamine
tetraacetate (EDTA), and 0.01% NaN3, stained with either
allophycocyanin- (APC-) conjugated CD36, phycoerythrin-
(PE-)conjugatedCD14(monocytediﬀerentiationantigen14
antibody), orﬂuorescein isothiocyanate- (FITC-)conjugated
CD42a (which recognize GPIb) [17], or appropriate isotype
controls (all from Becton Dickinson Biosciences, Franklin
Lakes, NJ, USA) and analyzed with the FACS Aria (Becton
Dickinson Biosciences) equipped with three air-cooled and
solid-state lasers (488-nm, 633-nm, and 407-nm). Dead cells
wereexcludedbySYTOXBlue(0.002mM,MolecularProbes,
Carlsband, Calif, USA) staining. MNC were then divided
into CD34pos and CD34neg populations using Magnetic
MultiSort Microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany). The CD34pos fraction was further divided into
CD36neg and CD36pos by sorting with the FACS Aria. The
CD34neg fractionwasenrichedforCD36pos andCD36neg cells
with Magnetic MultiSort Microbeads coated with CD36. All
thebead-basedcellenrichmentswereperformedasdescribed
by the manufacturer. CD36pos cells were further divided
into CD36low and CD36high by sorting. Whenever the cell
number allowed, the puriﬁed populations were reanalyzed
for purity and found >90% pure. Results were analyzed by
BD FACSDiva Software version 5.0.3.
2.3. Colony-Forming Assay. The colony forming ability of
unfractionated and sorted cells was evaluated in standard
semisolid methylcellulose cultures (40%, Fluka Biochemika)
stimulated with human SCF (10ng/mL), IL-3 (10ng/mL),
granulocyte-macrophage colony-stimulating factor (GM-
CSF, 10ng/mL), granulocyte colony-stimulating factor (G-
CSF, 100ng/mL) and EPO (5U/mL) [18]. The cultures were
incubated at 37◦C in a fully humidiﬁed 5% pCO2 atmo-
sphere and scored after 14 days for the growth of hematopoi-
etic colonies. CFU-GEMM-, BFU-E-, and CFU-GM-derived
colonies were recognized according to standard morpholog-
ical criteria [18, 19].
2.4. Ex Vivo Expansion of Human EBs under HEMA Con-
ditions. MNC (106 cells/mL) and prospectively isolated cells
(5×104 cells/mL) were culturedunder HEMA conditions, as
described [14]. Brieﬂy, the cultures contained Iscove’s mod-
iﬁed Dulbecco’s medium (IMDM, Lonza Group Ltd, Basel,
Switzerland) supplemented with fetal bovine serum (FBS,
Sigma-Aldrich) (20%v/v), detoxiﬁed human serum al-
bumin (HSA) (25%, Baxter International Inc, Deerﬁeld,Stem Cells International 3
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Figure 1: CD36/CD34 expression proﬁling ofAB MNC.(a) Representative coulter plot analyses for CD36/CD34 expression of MNC from a
representative AB and summaryof the frequency of the diﬀerent populations identiﬁed by thisanalyses.CD36/CD34 proﬁlingidentiﬁed ﬁve
populations: CD34posCD36neg cells (population A, red), CD34posCD36pos cells (population B, black),and CD34negCD36neg cells (population
E, green). A fourth CD34negCD36pos population contained numerous CD14pos cells which are represented by monocytes (see Figure 1(b)).
Exclusionof these CD14
pos cells from the analysesrevealed two CD34
neg/CD36
pos populations which express CD36 al low (CD34
negCD36
pos,
population C, purple) andhigh (CD34
negCD36
high cells, population D, blue) levels,respectively. The table onthe right summarizesthe mean
frequency (±SD) ofeachpopulationamongMNCobtainedfrom3diﬀerentdonors.Alltheresults presented inthisﬁgure andinFigure 2(a)
arepresented withthesamecolorcode.(b) Prospective isolationofABMNConthebasisofCD34/CD36 expression.MNCwereﬁrstdivided
in two populations enriched or deprived of CD34pos cells by CD34-coated magnetic bead adsorption. The CD34pos population was further
puriﬁed and divided into CD36neg and CD36pos cells by sorting. The CD34 beads ﬂow-through fraction (enriched for CD34neg cells) was
further divided into CD36
pos and CD36
neg cells by magnetic bead isolation. The cells eluted from the beads were puriﬁed by sorting on the
basis of lack of expression of CD14 and low level of CD36 expression (population C, purple). The CD14
negCD36
high cells (population D,
blue) were not isolated because expressed high levels of the megakaryocytic marker CD42a. Finally, the CD36 beads ﬂow-through fraction
was enriched for CD36neg cells by sorting. These CD36neg cells were also CD34neg upon reanalyses (not shown). Whenever feasible, the
prospectively isolated cells were reanalyzed for purity. Results are representative of those obtained in 3 independent puriﬁcations.4 Stem Cells International
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Figure 2: Growth and erythroid maturation of MNC prospectively isolated on the basis of CD34/CD36 proﬁling under HEMA conditions.
(a) Growth curve of cells prospectively isolated from AB MNC under HEMA conditions (the same color code as in Figure 1). MNC (grey
dotted line) were cultured in parallel as control. The number of cells present in the cultures is expressed as fold increase (FI). Results from
a representative experiment are shown. Similar results were observed in 2 additional experiments (see also Table 1). (b) Time course of the
maturation of EBs in HEMA cultures seeded with either AB MNC or with populations A, B, C, or E, as indicated. EBs maturation was
deﬁned on the basis of CD36/CD235a proﬁling which divides EBs into three populations: CD36posCD235a
neg/low (proerythroblasts, blue);
CD36pos/CD235a
med/high (basophilic erythroblasts, purple), and CD36lowCD235ahigh (orthochromatic erythroblasts, red). Forward and side
scatter analyzes identiﬁed a fourth population of small CD36lowCD235alow cells, probably represented by pyrenocytes (yellow). Cells which
do not express EB markersare indicated in green. The numbers within each quadrant indicate the frequency of the diﬀerent subpopulations.
Results are representative of those obtained in three independent experiments. nd = not done, due to low cell numbers.Stem Cells International 5
Table 1: Summary of the number of cells recovered in each fraction after CD36/CD34-based puriﬁcation and of their growth in HEMA
culture. Results with MNC and population A are presented as mean (±SD) of those obtained in three separate experiments. Results with
population E are representative of two independent experiments, while a complete data set for populations B and C is available only from
one experiment.
Cell population Cells obtained
from1 buﬀyc o a t
Recovery (%)∗ FI in HEMA
(Day 14)
Total theoretical number
of EBs generated in
HEMAat day 14∗∗
MNC 272 (±86) ×106 100% 10.1 ±1.42 .7 ×109
A CD34
posCD36
neg 75 (±53.5)× 10
3 27.5% 9,347 ±950 7.0 ×10
8
B CD34posCD36pos 9,500 3.5% 113 1.1 ×106
C CD34
negCD36
low 7,500 1.4 ×10
−3% 62.5 5.0 ×10
5
E CD34negCD36neg 2–10 ×106 1.0–4.9% 1.14–3.5 0.2–3.5 ×107
∗Recovery was calculated by dividing the total number of cells obtained after the puriﬁcation per the theoretical number of cells present in MNC. The theo-
retical cell number of each fraction was calculated by multiplying the frequency of the population, presented in Figure 1(a), per the average number of MNC
obtained from an AB buﬀy coat (272 ×106).
∗∗The theoretical total number of EBs obtainable at day 14 from each fraction was calculated by multiplyingthe total cell number of the fraction per the cor-
responding FI.
iLL, USA) [15], human SCF (50ng/mL, Sigma-Aldrich),
EPO (3U/mL, Neorecormon, Auckland, New Zealand) and
I L - 3( 1 0 n g / m L ,B i o s o u r c e ,S a nJ o s e ,C a l i f ,U S A ) ,D X M
(10−6 M) and ES (10−6 M) (both from Sigma-Aldrich), L-
glutamine (200mM, Euroclone SpA, Siziano, Italy), antibi-
otics [penicillin (10,000units/mL), streptomycin sulfate
(10,000μg/mL), fungizone (25μg/mL), Lonza Group Ltd],
and β-mercaptoethanol (10−6 M). The cultureswere keptfor
up to 10–15 days at 37◦Ca n d5 %p C O 2 in a fully humidiﬁed
incubator.
2.5.CellViability, PhenotypicAnalysisandSorting. Cellnum-
bers and viability were assessed by microscopic evalua-
tion after trypan blue (Boston Bioproducts, Ashland, Mass,
USA) staining. For ﬂow cytometrical characterization, cells
were suspended in Ca2+/Mg2+-free phosphate-buﬀered sa-
line,supplementedwith 1%BSA,2mmol/Lethylenediamine
tetraacetate (EDTA), and 0.01% NaN3, stained with either
allophycocyanin- (APC-) conjugated CD36 or phycoeryth-
rin- (PE-) conjugated CD235a (antiglycophorin A), or ap-
propriate isotype controls (all from Becton Dickinson Bio-
sciences) and analyzed with the FACS Aria. Dead cells were
excluded by SYTOX Blue (0.002mM, Molecular Probes)
staining. Forward and side scatter analyses of cells expressing
the mature CD36lowCD235ahigh phenotype and of small size
were used for the identiﬁcation of pyrenocytes [20].
2.6.Statistical Analysis. Resultsare presentedasmean (±SD)
of those obtained in at least three experiments per data set.
Mean (±SD) were calculated with the computer software
Origin5.0forWindows(MicrocalSoftware,Inc.,Northamp-
ton, Mass, USA).
3.Results
3.1. Antigenic Proﬁling of AB MNC. CD34/CD36 proﬁling
divided AB MNC into 4 populations: CD34posCD36neg
(populationA,0.1±0.05%),CD34posCD36pos (populationB,
often present in barely detectable numbers but reaching
in some donors a frequency of ∼0.1%), CD34negCD36pos
(∼23%) and CD34negCD36neg (population E, ∼74%)
(Figure 1(a)). CD34negCD36pos cells could in turn be divided
into three populations: the majority ofthemexpressed CD14
and was, therefore, represented by monocytes (monocytes
are known to express CD36) [21]( Figure 1(b)). By dot blot
distribution and CD42a staining, the remaining could be
divided into two additional populations: CD34negCD36low
(population C, ∼2%), which does not express CD42a, and
CD34negCD36high (population D, ∼1.0), which express high
levelsofCD42a(mean ﬂuorescence intensity, MFI > 15,000)
(Figure 1(b)).
3.2. Prospective Isolation of MNC Populations Based on CD34
and CD36 Expression. AB MNCs were puriﬁed on the basis
of CD34 and CD36 expression by the combination of mag-
netic bead enrichment and cell sorting described in
Figure 1(b).F i r s t ,C D 3 4 pos cells were enriched by selection
with CD34-coated microbeads. The CD34pos fraction (12%
pure by reanalyses) was then sorted into CD34pos cells
expressing (CD36pos, A population) or not (CD36neg, B pop-
ulation) CD36. Approximately 75,000 A cells and 10,000
B cells were recovered from the buﬀyc o a to fa na v e r a g e
donation (Table 1). Population A was >98% pure by re-
analyseswhilethepurityofpopulationBwasnotdetermined
due to low cell recovery.
Reanalyses for CD36 and CD14 expression of the ﬂow-
through fraction of the CD34-coated magnetic beads re-
vealed that a great number (∼78%) of CD36pos cells ex-
pressed also CD14. This ﬂow-through fraction was further
divided into CD36-enriched and CD36-deprived fractions
by CD36-magnetic bead isolation. The cells adsorbed to the
beads which did not express CD14and CD42aand expressed
CD36atlowlevelsweresorted(CD34posCD36low,population
C) (Figure 1(b)). Approximately7,500 C cells were recovered
from the buﬀy coat of a blood donation (Table 1). This
low number prevented reanalyses for purity of this cell
population and limited its functional characterization. The
CD14negCD34neg cells which expressed CD36 at high levels6 Stem Cells International
(CD34negCD36high, population D) was not sorted because of
its high CD42a expression, which suggest that the may have
been represented by megakaryocytic precursors [17].
The ﬂow-through fraction of the CD36 magnetic beads
was further puriﬁed by sorting (population E). A total of 10
million CD34negCD36neg cells were recovered from an aver-
age AB buﬀyc o a t( Table 1).
3.3. Cloning Eﬃciency ofAB PopulationsProspectively Isolated
on the Basis of CD34/CD36 Proﬁling. The progenitor cell
activityinsemisolidassaysofpopulationAandEispresented
in Table 2. AB MNC were analyzed in parallel as control.
As expected, population A was greatly enriched for colony
forming cells (cloning eﬃciency 16%) and generated both
BFU-E- and CFU-GM-derived colonies (in a 1:1 ratio).
It also contained few (0.001%) CFU-GEMM. By contrast,
population E had a cloning eﬃciency 40% lower than that
of MNC and generated mainly (80%) erythroid bursts. No
diﬀerence in size and morphology was observed among ery-
throid bursts originated from population A and E and MNC
(insert in Table 1), an indication that the BFU-E present in
the diﬀerent fractions had similar proliferation/maturation
potential.
3.4.Expansion PotentialunderHEMAConditionsofABPopu-
lations Prospectively Isolated on the Basis of CD34/CD36 Pro-
ﬁling. The expansion potential under HEMA conditions of
AB populations prospectively isolated on the basis of CD34/
CD36 proﬁling is compared in Figure 2(a) and Table 1.
AB MNC were analyzed in parallel as control. As expected,
under HEMA conditions, population A had great prolif-
eration potential expressing FIs between 900 (Figure 2(a))
and 24,000 (average FI = 9,000, Table 1)c o m p a r e dt oF I<
10 of the corresponding MNC. Signiﬁcant numbers of cells
were also generated by population B and C which expressed
FI of 100 and 60 by day 13 (Figure 2(a) and Table 1). By
contrast, population E had FI as low as 1–3. However, given
the great numbers of cells segregating in this fraction (>107),
population E generated many cells (∼107)u n d e rH E M A
conditions (FI ∼ 1).
3.5.MaturationPotentialofABMNCPopulationsProspective-
ly Isolated on the Basis of CD34/CD36 Proﬁling. The lineage
and maturation stage of the progeny of AB MNC and of AB
populations prospectively isolated on the basis of CD36/
CD34 proﬁling is presented in Figure 2(b). EBs maturation
was deﬁned on the basis of CD36/CD235a proﬁling which
divides EBs into three populations: CD36posCD235aneg/low
(pro-erythroblasts); CD36pos/CD235amed/high (basophilic
erythroblasts), CD36lowCD235ahigh (orthochromatic eryth-
roblasts) [5]. A fourth population of CD36lowCD235alow
cells with low forward and side scatter is composed by
pyrenocytes [20].
In cultures of MNC, cells with an immature EBs phe-
notype (CD36posCD235aneg) became detectable very quickly
(2% by day 2) while non-EBs became detectable in modest
numbers(6-7%)byday10.MatureEBs(CD36posCD235apos)
were detected by day 6 (15%) and reached a frequency >70%
by day10.By day15,immature EBsbecame barely detectable
and numerous cells with CD36lowCD235ahigh phenotype
(both larger cells corresponding to orthochromatic EBs,
18%, and smaller cells corresponding to pyrenocytes, 40%)
were detected (Figure 2(b)).
In HEMA cultures of population A, immature EBs were
also detected very early (10% by day 2) but the frequency
of mature EBs reached 10% only by day 8. By day 15, the
cultures contained signiﬁcant numbers (22%) of CD36low/
CD235ahigh orthochromatic EBs but no pyrenocytes
(Figure 2(b)).
In HEMA culture of population B, numbers of cells suf-
ﬁcient for antigenic proﬁling were obtained by day 6.
CD36posCD235aneg cells represented the majority (∼83%)
of the cells from day 6 to day 8. In these cultures, mature
CD36posCD235apos EBs were observed at earlier time points
with respect to cultures of population A (3% and 10% of
CD36posCD235apos cells by day 6-7 versusday 7-8 in cultures
of population B and A, resp.) (Figure 2(b)). By day 15, the
maturation phenotype of the progeny of population B and A
was the same.
HEMA cultures of population C were originally seeded
with number of cells comparable to those used for pop-
ulation A and B (∼7,500 cells with respect to 9,500–
10,000 cells used for the two other populations). However,
culturesofpopulationCgrewveryslow(seeFigure 2(a))and
the number of cells reached values suﬃcient for antigenic
proﬁling only by day 8. At day 8, great numbers (39%) of the
EBs had already the mature CD36pos/CD235ahigh phenotype.
However, the progeny of population C progressed poorly to
the orthochromatic stage and only 6% of them had acquired
the CD36lowCD235ahigh phenotype by day 15.
Finally, population E did not generate signiﬁcant num-
bers (26%) of CD36posCD235aneg cells until day 6. The
cells progressed then very rapidly to the CD36posCD235ahigh
stage (10%CD36posCD235ahigh cells by day 7) and CD36low
CD235ahigh stage (7.5% by day 13). Pyrenocytes were detect-
able in these cultures at levels similar to those observed in
cultures of MNC (24%) by day 15.
In conclusion, in spite of diﬀerences in kinetics, all the
populations analyzed in this study generated EBs under
HEMA conditions.
4.Discussion
CD36/CD34proﬁlingidentiﬁesatleastfourpopulationspre-
sent in AB MNC capable to generate colonies in semisolid
assay and EBs under HEMA conditions.
In semisolid assay, only 9% of the original HPCs activity
was recovered among the puriﬁed fractions (8.1% in popu-
lation A and 0.8% in population B). Although the cloning
eﬃciency of population B and C is not known, given the
low cell content of these populations (∼15,000 cells in total,
Table 1), they may contain at most 5% of the MNC HPCs
activity. Therefore, >80% of the HPCs activity present in the
MNC was lost during the puriﬁcation procedure. This result
suggests the hypothesis that some of the HPCs activity of
the MNC is due to pre-HPCs cells which became HPCs inStem Cells International 7
Table 2: Cloning eﬃciency of AB MNC and AB cell populations prospectively isolated on the basis of CD34/CD36 expression. Results
are presented as mean (±SD) of those observed in three independent experiments. The inserts present the morphology of a representative
BFU-E-derived colony obtained in the corresponding semisolidculture (original magniﬁcation 10x).
CFC/plate Total CFC
per fraction∗ Recovery
Cell population BFU-E CFU-GM CFU-GEMM
MNC
(105 cells/plate) 71 ±24 41 ±91 ±13 .1 ×105 100%
A CD34posCD36neg
(500cells/plate) 92 ±57 5 ±50 .5 ±0.52 .5 ×104 8.1%
E CD34negCD36neg
(105 cells/plate) 34 ±12 8 ± 32 ±12 .4 ×103 0.8%
∗The total number of CFC per fractionwas calculatedby multiplyingthe frequency of CFC (BFU-E + CFU-GM + CFU-GEMM) per the total number of cells
in the fraction presented in Table 1.
semisolid assay in response to factors released by accessory
cells.
Consistent with the data reported by van den Akkeret al.
[16], we determined that under HEMA conditions EBs are
generated both by CD34pos and CD34neg AB cells (Table 1).
Therefore, both populations contain EPC. CD34CD36 pro-
ﬁling identiﬁed that in addition to two CD34pos EPC
populations (CD34posCD36neg and CD44posCD36pos), AB
MNC contain 2 CD34neg EPC population (CD34negCD36low
and CD34negCD36neg). The antigenic proﬁle which deﬁnes
the CD34negCD36neg population is still to be identiﬁed,
although preliminary results indicate that these cells may
express CD44 [22], the receptor for hyaluronic acid which
interacts also with osteopontin and collagen [23]( d a t an o t
shown).
By contrast with the great loss of colony forming cells
observed with the puriﬁcation of AB MNC (Table 2), the
puriﬁcation procedures did not lead to great losses of EPC,
as indicated by the observation that the sum of the numbers
of EBs generated by the four puriﬁed fractions is only
modestly (7.5 × 108 versus 2.7 × 109) lower than that
generated by MNC (Table 1). Under HEMA conditions, the
population which generated the greatest numbers of EBs
was population A, only 27% of which had been recovered
during the puriﬁcation procedures (Table 1). Cultivation
under HEMA conditions of a population A containing all
the CD34posCD36neg cells present in one donation (100%
recovery)would generate asmany as 2.3×109 EBs, a number
very similar to that observed in cultures of MNC. These data
indicate cell loss during the puriﬁcation procedure, rather
than great EBs generation by CD34neg HPCs, as the main
reason for the overall greater output of EBs from MNC than
from CD34pos cells in HEMA culture.
Based on FI and on the time required to mature in cul-
ture, the four EPC populations identiﬁed in AB were clas-
siﬁed according to the hierarchical model presented in
Figure 3.C D 3 4 posCD36neg cells may represent earlier cells,
probably HPCs (they contain both BFU-E and CFU-GM),
while CD34posCD36pos and CD34negCD36pos cells may rep-
resents early and late erythroid restricted progenitor cells
(EPC), respectively. It is possible that these cell populations
are linked in a mother-daughter relationship. It is diﬃcult
to classify population E in this model. Since the majority
of the cells in this population is likely represented by
diﬀerentiated precursors, it is conceivable that the progen-
itor cells represent in this fraction are a rare population
with such a great proliferation potential to express FI = 1.
This hypothesis is also supported by the observation that
population E was the slowest population to generate EBs
(CD36posCD235apos cells were not detected before day 6). It
is suggested that this population may contain precursor cells
which are capable to generate CD34pos cells. Further studies
involving time course analyses of the expression of CD34
among the progeny of CD34negCD36neg E cells are required
to clarify this important point. Since the growth factors used
tostimulateHEMAculturewereselectedforoptimalEB,and
not CD34 cell, generation [15], it is possible that preculture
of CD34negCD36neg E cells under conditions which promote
CD34 cell proliferation (using growth factor combinations
includingFLT3ligandorthrombopoietic)[24,25],willallow
generation of greater numbers of EBs when the progeny of
their cells will be in turn cultured under HEMA conditions.
Also intriguing is the observation that population E is the
only puriﬁed populations to generate great numbers of
pyrenocytes by day 15, an indication that its progeny under-
wentsigniﬁcantlevelsofenucleationinHEMA.Thepresence
of macrophages greatly favors the enucleation process [26].
In HEMA culture, macrophages are present as contaminant
in cultures of MNC which routinely generate pyrenocytes
by day 15 (Figure 1(b)). These cells were removed by the
puriﬁcationprocessfromall theotherpopulationswhich did
not generate pyrenocytes by day 15. Population E, however,
although does not contain macrophages (CD14posCD36pos
cells) may contain their precursors, which may maturate
in culture, favoring enucleation of EBs. Further studies are
required to clarify the role of contaminating macrophages,8 Stem Cells International
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Figure 3: A model forthe hierarchical relationshipbetween progenitor cells with erythroid proliferation potential present in AB MNC. This
model is based of the proliferation potential (as indicated by the FI) and of the speed of maturation (as indicated by the time required to
generate signiﬁcant numbers, >25%, of mature CD235apos EBs) of the diﬀerent populations. See text for further details.
and/or of their precursor cells, in the enucleation of human
EBs generated under HEMA conditions.
In conclusion, CD34/CD36 proﬁling identiﬁes a hierar-
chy of EPC in AB. Although under HEMA conditions the
majority ofEBswere generatedbyCD34pos cells, itispossible
that further improvement of the culture system by favoring
proliferation ofCD34neg cells, may further increase thenum-
ber of EBs generated by AB.
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